会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • 9-(3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro-[3′,4′:6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one compounds
    • 9-(3,5-二甲氧基苯基)-5,8,8a,9-四氢呋喃(3',4':6,7)萘并(2,3-d)(1,3)二氧杂环戊烯-6(5aH) 一种化合物
    • US06281198B1
    • 2001-08-28
    • US09697248
    • 2000-10-26
    • Claude MonneretEmmanuel BertounesquePhilippe MeresseGhanem AtassiAlain PierreBruno PfeifferPierre Renard
    • Claude MonneretEmmanuel BertounesquePhilippe MeresseGhanem AtassiAlain PierreBruno PfeifferPierre Renard
    • A61K31365
    • C07D493/04Y02P20/55
    • Compound of formula (I): wherein: R represents: a group of formula (i):  wherein X, Y and W are as defined in the description, or a group of formula (ii): —A—G  (ii) wherein: A represents a single bond or an optionally substituted alkylene chain, G represents a group selected from hydrogen, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —OR2, —O—T1—NR3R4, —O—T1—NR2—T′1—NR3R4, —NR3R4, —NR2—T1—NR3R4, —NR2—T1—OR5, —NR2—T1—CO2R6, —NR2—T1—C(O)R6, —C(O)—NR3R4, —C(O)—NR2—T2, —O—C(O)T2, —O—C(S)—T2, —NR2—C(O)—T2, —NR2—C(S)—T2, —O—C(O)—O—T2, —O—C(O)—NR2—T2, —O—C(S)—O—T2, —O—C(S)—NR2—T2, —NR2—C(O)—O—T2, —NR2—C(O)—NR—T2, —NR2—C(S)—O—T2, —NR2—C(S)—NR6—T2 and —NR2—SO2—T3,  wherein R2, R3, R4, R5, R6, T1, T′1, T2 and T3 are as defined in the description, R1 represents a group selected from hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, heterocycloalkylcarbonyl, alkylsulphonyl, arylsulphonyl, arylalkylsulphonyl, phosphono, aryloxycarbonyl, alkoxycarbonyl and arylalkoxycarbonyl, its isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of cancer.
    • 式(I)的化合物:其中:R表示:式(ⅰ)的基团:其中X,Y和W如说明书中所定义,或式(ⅱ)的基团:其中:A表示单键或 任选取代的亚烷基链,G表示选自氢,环烷基,杂环烷基,芳基,杂芳基,-OR2,-O-T1-NR3R4,-O-T1-NR2-T'1-NR3R4,-NR3R4,-NR2 -T 1 -NR 3 R 4,-NR 2 -T 1 -OR 5,-NR 2 -T 1 -CO 2 R 6,-NR 2 -T 1 -C(O)R 6,-C(O)-NR 3 R 4,-C(O)-NR 2 -T 2,-OC (O)T 2,-OC(S)-T 2,-NR 2 -C(O)-T 2,-NR 2 -C(S)-T 2,-OC(O)-O-T 2,-OC(O) -T 2,-OC(S)-O-T2,-OC(S)-NR2-T2,-NR2-C(O)-O-T2,-NR2-C(O)-NR-T2, C(S)-O-T2,-NR2-C(S)-NR6-T2和-NR2-SO2-T3,其中R2,R3,R4,R5,R6,T1,T'1,T2和T3为 R 1表示选自氢,烷基,芳基,芳基烷基,杂芳基,杂芳基烷基,烷基羰基,芳基羰基,芳基烷基羰基,杂环烷基羰基,烷基磺酰基,芳基磺酰基,芳基烷基磺酰基,膦酰基,芳氧基羰基,烷氧基羰基和 芳基烷氧基羰基,其异构体,以及其与药学上可接受的酸或碱的加成盐。含有该化合物的药物可用于治疗癌症。
    • 3. 发明授权
    • Dihydrofuro[3,4-b]quinolin-1-one compounds
    • 二氢呋喃并[3,4-b]喹啉-1-酮化合物
    • US06548515B1
    • 2003-04-15
    • US09718917
    • 2000-11-22
    • Henri-Philippe HussonSylviane Giorgi-RenaultChristophe TratratGhanem AtassiAlain PierrePierre RenardBruno Pfeiffer
    • Henri-Philippe HussonSylviane Giorgi-RenaultChristophe TratratGhanem AtassiAlain PierrePierre RenardBruno Pfeiffer
    • A61K314741
    • C07D491/04C07D219/06C07D221/16C07D221/18C07D491/14C07D495/04
    • The invention relates to compound of formula (I): wherein: represents a single or double bond, R0 represents hydrogen or hydroxy or alkoxy, R1 and R2, which are identical or different, each represents hydrogen or halogen or alkyl, alkoxy, hydroxy, polyhaloalkyl, nitro or optionally substituted amino or  wherein m represents an integer such that 1≦m≦4, or form together with the carbon atoms carrying them an aromatic or non-aromatic, mono- or bi-cyclic group having from 5 to 12 ring members and optionally containing 1 or 2 hetero atoms selected from O, S and N, R3 represents hydrogen or aryl, heteroaryl, cycloalkyl, optionally substituted alkyl or a group of formula COR7 wherein R7 represents aryl, optionally substituted alkyl, optionally substituted amino or OR10 wherein R10 represents aryl or optionally substituted alkyl, X represents oxygen or sulphur or —CH2— or —CH2—CH2—, Ar represents aryl, heteroaryl or arylalkyl, its optical isomers, its hydrates, solvates, and also its addition salts with a pharmaceutically acceptable acid. Medicinal products containing the same are useful in the treatment of cancer.
    • 本发明涉及式(I)的化合物:其中:表示单键或双键,R 0表示氢或羟基或烷氧基,R 1和R 2相同或不同,各自表示氢或卤素或烷基,烷氧基,羟基,多卤代烷基,硝基或任选取代的氨基或 其中m表示1≤= m = 4的整数,或与带有带有5至12个环成员的芳族或非芳族单环或双环基团的碳原子一起形成,并且任选地含有1或 2个选自O,S和N的杂原子,R 3表示氢或芳基,杂芳基,环烷基,任选取代的烷基或式COR7基团,其中R7表示芳基,任选取代的烷基,任选取代的氨基或OR 10,其中R 10表示芳基或任选地 取代的烷基,X表示氧或硫或-CH 2 - 或-CH 2-CH 2 - ,Ar表示芳基,杂芳基或芳基烷基,其光学异构体,其水合物,溶剂合物,以及其与药学上可接受的酸的加成盐。含有它们的医药产品可用于治疗癌症。